Catalog No.S8246

For research use only.

RK-33 is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.

RK-33 Chemical Structure

CAS No. 1070773-09-9

Selleck's RK-33 has been cited by 14 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Other DNA/RNA Synthesis Products

Biological Activity

Description RK-33 is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.
DDX3 [1]
In vitro

RK-33 binds specifically to DDX3, but not to the closely related proteins DDX5 and DDX17. RK-33 inhibits cancer growth and radiosensitizes lung cancer cells in a DDX3-dependent manner. RK-33 has no effect on either mitochondrial respiration or ATP generation. RK-33 curbs proliferation and induces apoptosis in a DDX3-dependent fashion. Wnt signaling is mediated by DDX3 and inhibited by RK-33. RK-33 impairs radiation-induced DNA damage repair by inhibiting NHEJ activity[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MoHPR5l1d3SxeHnjbZR6KGG|c3H5 NXzMV4tKPzJiaILz MkLWR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVOSCjc4PhfUwhUUN3MDC9JFIvPSEQvF2u MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW0NUc,OjF3N{K1OFE9N2F-
A549 MYTDfZRwfG:6aXPpeJkh[XO|YYm= MoeyO|IhcHK| MnqwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgW3NVOSCjc4PhfUwhUUN3MDC9JFIvPTZizszNMi=> Mn7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{OUCyOVIoRjJ|MkmwNlUzRC:jPh?=
H460 M3GxXmN6fG:2b4jpZ4l1gSCjc4PhfS=> NGDaSGw4OiCqcoO= MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3QyKGG|c3H5MEBKSzVyIE2gNk45KM7:TT6= M{jqd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVQyLz5{MUW3NlU1OTxxYU6=
H460 NWewNHdIS3m2b4TvfIlkcXS7IHHzd4F6 M1HFblczKGi{cx?= M1vTU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHdUXDFiYYPzZZktKEmFNUCgQUAzNjh5IN88UU4> NXnPT4dvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyPVAzPTJpPkKzNlkxOjV{PD;hQi=>
MDA-MB-231 M1[2RmN6fG:2b4jpZ4l1gSCjc4PhfS=> MVy3NkBpenN? MmH1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUNUBie3OjeTygTWM2OCB;IESuNFEh|ryPLh?= NFrKc4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU1OSd-MkG1O|I2PDF:L3G+
MDA-MB-231 NXzEUphWS3m2b4TvfIlkcXS7IHHzd4F6 NHfm[HU4OiCqcoO= MlviR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDh[pRmeiB5MjDodpMh[nliV2PUNUBie3OjeTygTWM2OCB;IESuNFUh|ryPLh?= NXLyV5M2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyPVAzPTJpPkKzNlkxOjV{PD;hQi=>
PC3 M4P2emN6fG:2b4jpZ4l1gSCjc4PhfS=> NEX5PFc4OiCqcoO= NHrTdoZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHdUXDFiYYPzZZktKEmFNUCgQUA1NjhizszNMi=> NFTLcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU1OSd-MkG1O|I2PDF:L3G+
PC3 NV3OeHhZS3m2b4TvfIlkcXS7IHHzd4F6 MlexO|IhcHK| MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGfTWFEh[XO|YYmsJGlEPTBiPTC0Mlkh|ryPLh?= NEfGelI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K5NFI2Oid-MkOyPVAzPTJ:L3G+
MCF7 MnGzR5l1d3SxeHnjbZR6KGG|c3H5 NVPhc4dCPzJiaILz MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDXV3QyKGG|c3H5MEBKSzVyIE2gO{42KM7:TT6= M2PPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVQyLz5{MUW3NlU1OTxxYU6=
MCF7 MoLMR5l1d3SxeHnjbZR6KGG|c3H5 NHL1NIY4OiCqcoO= M3LQPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JHdUXDFiYYPzZZktKEmFNUCgQUA4NjV7IN88UU4> M2nVdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkmwNlUzLz5{M{K5NFI2OjxxYU6=
OVCAR3 NI\DT2dEgXSxdH;4bYNqfHliYYPzZZk> NFrXe|U4OiCqcoO= M4r4ZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG9XS0GUMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhX1OWMTDhd5NigSxiSVO1NEA:KDF2LkWg{txONg>? MmjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1OFEoRjJzNUeyOVQyRC:jPh?=
OVCAR3 M4qwdmN6fG:2b4jpZ4l1gSCjc4PhfS=> MWi3NkBpenN? NYnwfox4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hV1[FQWKzJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCZU2SxJIF{e2G7LDDJR|UxKD1iMUSuOUDPxE1w M17kWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|MkmwNlUzLz5{M{K5NFI2OjxxYU6=
Methods Test Index PMID
Western blot DDX3 ; Cyclin D1 / Cyclin E1 30292066 25820276
Growth inhibition assay Cell viability 27634756
In vivo RK-33 in combination with radiation induces tumor regression in multiple mouse models of lung cancer. RK-33, at the dose used, is non-toxic in SCID mice. RK-33-treated mice do not exhibit any discernable morphological changes[1].

Protocol (from reference)

Cell Research:


  • Cell lines: MDA-MB-231 cells
  • Concentrations: 7.5 μM
  • Incubation Time: 12 h
  • Method:

    Healthy, 60-70% confluent MDA-MB-231 cells are transduced with shDDX3 lentivirus particles. Knockdown of DDX3 expression is confirmed both by qRT-PCR and immunoblotting. MDA-MB-231 cells are treated with RK-33 (7.5 μM) for 12 h and harvested for RNA. Microarray experiments are performed.

Animal Research:


  • Animal Models: SCID mice
  • Dosages: 20 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 428.44


CAS No. 1070773-09-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=CC=C(C=C1)CN2C=NC3=C2N=CN=C4C3=NC(=O)N4CC5=CC=C(C=C5)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy RK-33 | RK-33 supplier | purchase RK-33 | RK-33 cost | RK-33 manufacturer | order RK-33 | RK-33 distributor